The use of biologics in chronic rhinosinusitis with polyps: Saudi otorhinolaryngology society position statement

Alsaleh, Saad; Alqahtani, Abdulaziz; Alotaibi, Naif H.; Alfawwaz, Fahad; Aloulah, Mohammad; Almasoud, Mai; Al-Bar, Mohammad H.; Alzarei, Ali; Marglani, Osama; Asiri, Saad

doi:10.4103/sjoh.sjoh_29_20

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This includes a position paper from the Saudi Otorhinolaryngology Society, principally endorsing the recommendations made by EPOS 2020 regarding use of biologics in CRSwNP. 15 More recently, guidance on use of biologics in CRSwNP from an expert panel of otorhinolaryngology (ORL) and respiratory physicians from the broader Gulf region has also recently been published. 16 Building upon these previous initiatives, an expert panel was convened to re-evaluate existing guidelines such as EPOS 2020 and their application to the current management of CRSwNP within the pan-Arab region.…”

Section: Introductionmentioning

confidence: 99%

Management of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in the Pan-Arab Region: Consensus Recommendations from a Multidisciplinary Expert Working Group

Marglani,

Al Abri,

Al Ahmad

et al. 2023

JAA

Self Cite

View full text Add to dashboard Cite

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic and often debilitating inflammatory condition of the nasal and paranasal tissues. An expert panel of specialists from the Gulf region (the Kingdom of Saudi Arabia, Kuwait, Oman and the United Arab Emirates) and from Egypt gathered to evaluate existing guidance and develop regional guidance on the management of CRSwNP through a consensus approach. The present article presents the main observations and recommendations from this panel. CRSwNP diagnosis requires the presence of bilateral, endoscopically visualized polyps in the middle meatus (via nasal endoscopy or CT). In most patients, CRSwNP is mediated through predominantly type 2 inflammatory processes and is often observed in patients with asthma and other allergic disease. While many patients respond to medical treatment (principally topical irrigation and intranasal corticosteroids, and adjunctive short-term use of systemic corticosteroids), clinical management of CRSwNP is challenging, and a multidisciplinary approach for complete evaluation and treatment is recommended. Patients with more severe/uncontrolled disease (despite adequate medical therapies) require a complete endoscopic sinus surgery (ESS), although outcomes can be unsatisfactory, and further revision surgery is common. Biological therapies targeting underlying inflammatory processes offer additional, effective treatment options for those patients with persistent symptoms despite complete ESS, and also in those patients where surgery may be contraindicated.

show abstract

Section: Introductionmentioning

confidence: 99%